In the United States, biosimilar launches have been met with disappointment over what many view as too-shallow discounts to reference products’ list prices. However, as Aurelio Arias, a consultant at IQVIA, explained during the SMi 9th annual conference on Biosimilars and Biobetters, held September 26-27 in London, United Kingdom, the substantial savings that the European market has realized with biosimilars are not necessarily reflected in list prices, either.
In the United States, biosimilar launches have been met with disappointment over what many view as too-shallow discounts to reference products’ list prices.
However, as Aurelio Arias, a consultant at IQVIA, explained during the SMi 9th annual conference on Biosimilars and Biobetters, held September 26-27 in London, United Kingdom, the substantial savings that the European market has realized with biosimilars are not necessarily reflected in list prices, either. Arias noted that in Europe, discounts on list prices at the time of launch are not that much greater than they are in the United States, as most European biosimilars appear to launch at a 10% to 20% discount to the originator. These are “not necessarily the huge savings we were promised initially,” he said.
However, net pricing is likely to tell a different story. While Arias explained that net pricing is similar to “the dark arts” and can be difficult to assess, the available data in Europe show that health systems are achieving discounts of as much as 70% for some drugs, primarily for molecules that have 3 biosimilar products available.
He noted that the number of entrants above 3 did not make a substantial impact on price, however, and that in nations where only a single manufacturer can win a tender, average net costs are higher than they are in countries that have multiple-winner tenders.
The discounts that health systems have been able to achieve have proven to be deep enough to drive substantial uptake (Arias cited approximately 70% uptake for biosimilar trastuzumab in the Netherlands 2 months after the first product launched), even when adopting a biosimilar means forgoing newer devices or routes of administration.
According to Arias, in some health systems that had previously moved patients with HER2-positive cancer to subcutaneous administration of the reference trastuzumab (Herceptin), clinicians reverted to intravenous administration of the reference product as a way to prepare patients for the switch to the intravenous biosimilar.
Overcoming the challenge of moving patients to a biosimilar version of adalimumab may be even less of a challenge; while Humira maker AbbVie has created a reformulated version of the reference drug—administered with a slightly smaller needle that is designed to cause less pain at the injection site—Arias says that physicians and health systems are likely to trade a minor difference in patient discomfort for substantial cost savings. In fact, he noted, some health systems are reporting that they plan to run their stocks of Humira dry so that they can replenish their pharmacies with a biosimilar product on the first day of their tender agreements.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.